



Research & Development in Australia (CONSUMER)

Amgen has been conducting business in Australia since 1992. Through the ongoing introduction of new medicines, the company has helped thousands of patients in Australia and New Zealand in their fight against serious illness.

An Interdisciplinary Approach to Research and Development

Over the past 25 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. Today, Amgen scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology, in an effort to discover and develop the medical breakthroughs of tomorrow. We focus on pioneering treatments for serious illness. As part of that commitment, our R&D organisation has cultivated expertise in multiple treatment methods – large-molecular proteins, small molecules and antibodies – allowing us to choose the best target for attacking disease and to use the method most likely to affect that target.

Investment in Research

Amgen leads the industry in its financial commitment to research and development. In 2006, 40 per cent (\$US 3.2 billion) of the year's total global product sales were reinvested in research & development functions. In 2007, Amgen Australia invested in excess of \$30 million (AUD) in local research and development. Investment in 2008 is likely to be similar.

Research Areas include

Oncology	Haematology
Neuroscience	Inflammation
Bone and metabolic disorders	General medicine (including Nephrology)

Clinical Trials

While Amgen established offices in Australia in 1991, clinical research in the region actually started much earlier. Since 1987, Amgen Australia has been involved in over 180 clinical trials.

Currently, there are nearly 60 active studies across 4 therapeutic areas (Oncology, Inflammation, General Medicine [including Nephrology] and Bone). Over half of these studies are in Oncology. These activities are conducted in more than 100 hospitals and research centres in Australia and there are over 1,500 Australian patients currently taking part in these trials.

Since 1991, almost 5,500 patients have participated in trials run by Amgen Australia. Approximately 50 per cent of Amgen's trials in Australia are in early phase (1 or 2).

Quick Facts

Primary Location

Head Office - Sydney

Contact details

Head Office (Sydney)
Amgen Australia Pty Ltd
Level 7, 123 Epping Road
North Ryde NSW 2113
Australia

DID YOU KNOW?

Australia consistently contributes 10 per cent of patients to the global pool of studies in which we participate.

Partnerships

Amgen understands we can nurture advances in medicine and technology beyond our company through relationships with scientists and research institutes.

As an important component of our overall outreach strategy, Amgen invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The program, which focuses primarily on areas of current therapeutic interest to Amgen, offers early-stage companies access to our extensive capabilities while providing us with insight into external research innovations that may pave the way for future collaborations. This program has operated in Australia since 2004 and we currently have agreements with a number of Australian research institutes.

Research and Educational Grants

Amgen Australia supports clinical research and ongoing medical education in the form of Grants and Awards. In 2007, the following awards were supported:

- Medical Researcher Award (The Australian Society for Medical Research)
- Renal Society of Australasia Renal Nurse Grants
- Kidney Health Australia (KHA) Biomedical Scholarship
- Medical Oncology Group of Australia (MOGA) Advanced Trainees Grant
- ANZ Children's Health Oncology Group (ANZCHOG) Travel Grants
- Cancer Nurses Society of Australia (CNSA) International Travel Grant
- Haematology Society of Australia & New Zealand (HSANZ) Young Investigator Scholarship
- Australian & New Zealand Bone & Mineral Society (ANZBMS) Christine and T Jack Martin Research Travel Grant

Amgen Australia also provided funding for research and medical education to key health consumer organisations and professional bodies including:

- Australia & New Zealand Society of Nephrology (ANZSN)
- Renal Society of Australia (RSA)
- Transplant Society of Australia & New Zealand (TSANZ)
- Cochrane Renal Group
- Society of Hospital Pharmacists Australia (SHPA)
- Leukaemia Foundation
- ANZSN Postgraduate Workshop
- Australian Society of Bone & Mineral Research (ANZBMS)
- Garvan Institute for Medical Research (Dubbo Osteoporosis Epidemiology Study)
- Australian Society of Thrombosis & Haemostasis (ASTH)
- Osteoporosis Australia
- Australia Leukaemia and Lymphoma Group (ALLG)